Analysis of drug differences and efficacy of Pazopanib in patients with lung cancer and kidney cancer

Pazopanib (Pazopanib) is a multi-target oral tyrosine kinase inhibitor (TKI), which mainly acts on VEGFR, Targets such as span>PDGFR, FGFR and c-Kit have significant anti-angiogenic effects. The drug was initially approved for the treatment of advanced renal cell carcinoma (RCC) and soft tissue sarcoma, but in recent years has also been studied for use in a variety of solid tumors, including non-small cell lung cancer. Due to different tumor types, biological characteristics and disease progression patterns, there are obvious differences in the drug effects and application strategies of pazopanib in patients with lung cancer and renal cancer.

For patients with advanced renal cancer, pazopanib is used as a first-line targeted therapy, and its efficacy has been confirmed by multiple clinical studies. In the COMPARZ study, pazopanib performed comparably with sorafenib on overall survival (OS), but had better quality of life scores and lower rates of adverse effects. In RCC patients, pazopanib can significantly prolong progression-free survival (PFS). Common side effects include hypertension, fatigue and abnormal liver function, and most of them can be alleviated through dose adjustment. Therefore, in the treatment of renal cancer, pazopanib has become the first-line treatment drug recommended by international guidelines.

In non-small cell lung cancer (NSCLC), the application of pazopanib is still in the exploratory stage. Studies have shown that it may have certain efficacy in certain highly vascularized lung cancer subtypes (such as adenocarcinoma), but compared with other approved first-line targeted drugs (such as EGFR or ALK inhibitors), the therapeutic effect of pazopanib is relatively limited. Some phase II trials have shown that pazopanib can delay disease progression in patients with chemotherapy-resistant NSCLC, but the objective response rate is low and the main manifestation is stable disease. Therefore, the application of pazopanib in lung cancer has not yet become a mainstream treatment option, and is more used in clinical trials or auxiliary research.

In summary, pazopanib is a mature and effective first-line targeted therapy option in renal cancer, while it is still in research and supplementary status in the field of lung cancer. Therapeutic strategies should be tailored to the specific tumor type, patient mutational status, and tolerability. In the future, if it can be combined with more precise classification or combined with immunotherapy, pazopanib may have greater potential in lung cancer, but more clinical data are still needed to verify it.

Reference materials:https://www.drugs.com/